
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is positioned as a leader in developing next-generation programmed T-cell therapies for the treatment of cancer, specifically B-ALL. The company's clinical-stage pipeline, including Obe-cel, AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8, has promising potential for commercial use and could attract investor interest. Though Aucatzyl's potential in treating autoimmune diseases is a positive sign, the limited research in this area makes it a riskier option compared to its established use for B-ALL.
Bears say
Autolus Therapeutics is in a crowded market, with several other companies also developing CD19 CAR-T therapies for the treatment of cancer. Additionally, there is uncertainty with the company's pipeline, as their Phase 1 BOBCAT trial for Obe-cel in progressive MS is not expected to have initial data until 2026 and there may be challenges in commercializing their therapies due to high costs and production limitations. While the company has had some success with Aucatzyl, there is no guarantee that they will be able to replicate this success with their other therapies, and the potential for reduced market potential and regulatory setbacks could significantly impact their financial performance.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares